G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: Caveolin-1 as a marker of cytotoxicity

Anti-Cancer Drugs

Volumn 15, Issue 10, 2004, Pages 961-967

  Roussel, Élise ^a   Bélanger, Martin M ^a   Couet, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Caveolae; Caveolin; Lung cancer; Paclitaxel

Indexed keywords

CAVEOLIN 1; PACLITAXEL; TUMOR MARKER; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; CAVEOLIN;

ARTICLE; CANCER CELL CULTURE; CAVEOLA; CELL ADHESION; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LOW DRUG DOSE; LUNG CANCER; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; APOPTOSIS; BIOSYNTHESIS; CELL DIVISION; DOSE RESPONSE; LUNG TUMOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAVEOLIN 1; CAVEOLINS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; UP-REGULATION;

EID: 9344268823     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200411000-00005     Document Type: Article

References (31)

1. Couet J, Belanger MM, Roussel E, Drolet MC. Cell biology of caveolae and caveolin. Adv Drug Deliv Rev 2001; 49:223-235.
2. Okamoto T, Schlegel A, Scherer PE, Lisanti MR Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J Biol Chem 1998; 273:5419-5422.
3. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19:7289-7304.
4. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, et al. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 1997; 272:33416-33421.
5. Couet J, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain (CSD). Implications for the interaction of caveolin with caveolin-associated proteins. J Biol Chem. 1997; 272:6525-6533.
6. Toya Y, Schwencke C, Couet J, Lisanti MP, Ishikawa Y. Inhibition of adenylyl cyclase by caveolin peptides. Endocrinology 1998; 139: 2025-2031.
7. Li S, Couet J, Lisanti MP. Src tyrosine kinases, G alpha subunits and H-Ras share a common membrane-anchored scaffolding protein, Caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996; 271:29182-29190.
8. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17:6633-6648.
9. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276:38121-38138.
10. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998; 428: 205-211.
11. Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MR p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 1999; 274:32333-32341.
12. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MR Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997; 272: 16374-16381.
13. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999; 255:580-586.
14. Belanger MM, Roussel E, Couet J. Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 2003; 14:281-287.
15. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999; 83:151-156.
16. Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 2002; 1:113-117.
17. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998; 439:368-372.
18. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90:9552-9556.
19. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92: 1381-1385.
20. Liu J, Lee P, Galbiati F, Kitsis RN, Lisanti MP. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 2001; 280:C823-C835.
21. Gargalovic P, Dory L. Cellular apoptosis is associated with increased caveolin-1 expression in macrophages. J Lipid Res 2003; 44:1622-1632.
22. Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell 2002; 13:2502-2517.
23. Massimino ML, Griffoni C, Spisni E, Toni M, Tomasi V. Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis. Cell Signal 2002; 14:93-98.
24. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273:32380-32383.
25. Lavie Y, Fiucci G, Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev 2001; 49:317-323.
26. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61:4386-4392.
27. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4:1062-10644.
28. Huristone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999; 18:1881-1890.
29. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19:3256-3265.
30. Kung AL, Sherwood SW, Schimke RT. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 1990; 87:9553-9557.
31. 1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996; 135:689-700.